All In Biotech

Drug Trial Radar · NCT07612150

A Study to Evaluate the Safety, Tolerability, and Efficacy of TML-6 in Participants With Early Alzheimer's Disease

An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Aug 1, 2026

Primary completion

Apr 30, 2028

Study completion Jul 31, 2028

Sponsor

Sponsor type
Industry
First posted
May 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to assess if treatment with TML-6 for 52 weeks will be effective in slowing, stopping, or improving cognitive and functional decline in participants with early Alzheimer's Disease (AD) as compared to participants receiving placebo.

Conditions

  • Alzheimer Disease

Interventions

  • TML-6Drug

    TML-6 tablets for oral administration.

  • PlaceboOther

    TML-6 matching placebo tablets for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Clinical Dementia Rating -Sum of Boxes (CDR-SB) Score at Week 52Time frame: Baseline and at Week 52

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.